SAB Biotherapeutics (NASDAQ: SABS) revenue
SAB Biotherapeutics reported revenue of $0.0m for fiscal 2025, 100.0% less than in fiscal 2024 ($1.3m).
SAB Biotherapeutics's revenue has fallen for 4 years in a row, and its best year of the last 6 was fiscal 2021. The biggest drop was in fiscal 2023, −90.6%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.0m | −100.0% | −$49.0m | — |
| 2024 | $1.3m | −40.9% | −$42.9m | −3,244.9% |
| 2023 | $2.2m | −90.6% | −$38.1m | −1,700.6% |
| 2022 | $23.9m | −60.7% | −$28.9m | −121.0% |
| 2021 | $60.9m | +10.2% | −$13.4m | −22.0% |
| 2020 | $55.2m | — | $20.6m | 37.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
SAB Biotherapeutics revenue compared with its sector
By revenue for its latest fiscal year, SAB Biotherapeutics ranks 417th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; SAB Biotherapeutics, −100.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 415th | Rocket Pharmaceuticals | $0.0m | — |
| 416th | Revolution Medicines | $0.0m | — |
| 417th | SAB Biotherapeutics | $0.0m | −100.0% |
| 418th | Spruce Biosciences | $0.0m | −100.0% |
| 419th | Scholar Rock | $0.0m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of SAB Biotherapeutics
- How much revenue did SAB Biotherapeutics make in fiscal 2025?
- SAB Biotherapeutics reported revenue of $0.0m for fiscal 2025, compared with $1.3m in fiscal 2024.
- What was the best year for revenue at SAB Biotherapeutics?
- Of its last 6 fiscal years, fiscal 2021, with $60.9m.
- Where does SAB Biotherapeutics rank in its sector by revenue?
- It ranks 417th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for SAB Biotherapeutics come from?
- From the annual report (Form 10-K) that SAB Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that SAB Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on SAB Biotherapeutics: the SAB Biotherapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.